HD-OPM Archive

Inflammation and hs-CRP: the residual risk

Why inflammation is now treated as a real driver of atherosclerosis alongside cholesterol, what hs-CRP can and cannot tell you, how the major trials (CANTOS, ZEUS, colchicine studies) fit together, and which lifestyle and drug options the group discusses for lowering it.

16 min read56 group posts cited51 studies discussed4 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • hs-CRP is read in three bands (under 1 mg/L lower risk, 1 to 3 average, over 3 higher), and in the Women's Health Study the top fifth of hs-CRP carried a hazard ratio of 1.70 for cardiovascular events over 30 years, versus 1.36 for LDL and 1.33 for Lp(a).
  • hs-CRP is a systemic signal, not an artery-specific one. Infections, hard workouts, arthritis flares, visceral fat and ageing skin all raise it, so one reading is unreliable and averaging repeated measurements is recommended.
  • In statin-treated PCI patients with LDL under 70 mg/dL, hs-CRP of 2 mg/L or more went with about 1.8 times more major adverse cardiac events, while high triglycerides alone showed no significant increase.
  • Lowering a marker is not the same as lowering risk. In the 2026 ZEUS trial ziltivekimab cut CRP by 64 percent and IL-6 by 76 percent, yet events were 17.6% versus 17.7% on placebo.
  • Low-dose colchicine (0.5 mg) is FDA approved to reduce cardiovascular events, and statins, bempedoic acid, a Mediterranean or DASH diet, exercise and omega-3s all lower hs-CRP to varying degrees.
In this summary
  1. What inflammation does in the artery wall
  2. Measuring it: hs-CRP and its limits
  3. What the trials show
  4. Nuances and controversies
  5. How to lower it: what the group discusses
  6. What this means for you
  7. Frequently asked questions
  8. The evidence behind this summary

Inflammation is the body's alarm system, and in atherosclerosis it is switched on inside the artery wall. Cholesterol particles that lodge in the wall are treated by the immune system as something to attack, and the resulting battle shapes how plaque forms, grows and eventually ruptures12. This is why some people who have excellent LDL cholesterol on a statin still have heart attacks. The leftover danger is often called "residual risk", and inflammation is thought to be a large part of it34.

The everyday blood test for this is high-sensitivity C-reactive protein (hs-CRP). It is cheap and widely available, and a 2025 American College of Cardiology (ACC) Scientific Statement recommended measuring it alongside cholesterol in both primary and secondary prevention56. But hs-CRP is a blunt instrument: it tells you there is a fire somewhere in the body, not where. This article explains what the test means, what the trials show, where the evidence is mixed, and what the group's admins suggest discussing with a doctor.

1.70hazard ratio for cardiovascular events in women with the highest fifth of hs-CRP, over 30 years7
Up to halfof US adults have an hs-CRP of 2 mg/L or higher5
1.8×more major adverse cardiac events with hs-CRP of 2 or more, despite LDL under 70 on a statin3
64%fall in CRP on ziltivekimab in ZEUS, with no fewer heart attacks, strokes or cardiovascular deaths8

What inflammation does in the artery wall

Atherosclerosis is now understood by the group's sources as a chronic inflammatory disease of the artery wall, with immune cells and inflammatory signaling involved from the first deposit of plaque to its rupture25. Peter Libby describes it as a disease of constant cellular conflict inside plaques, with superficial erosion increasingly recognized as a cause of clots, and with bone marrow signaling and clonal hematopoiesis (blood stem cells carrying age-related mutations) driving white cells into plaques11.

A chain of signals links the plaque to the blood test. According to a summary by Gokhan Can, cholesterol crystals in a plaque activate the NLRP3 inflammasome, which releases the master cytokine IL-1 beta. IL-1 beta stimulates IL-6, and IL-6 makes the liver produce CRP2. A Scientific American article shared by Louis Nervegna puts it simply: cholesterol is the match that lights the fire of vascular inflammation1. Louis also adds that LDL which enters the wall and oxidizes attracts immune cells, which is one reason LDL-lowering drugs also lower hs-CRP12.

Gokhan Can has summarized preclinical work suggesting that high LDL also acts earlier, at the level of the bone marrow. In mouse studies, high cholesterol pulled blood stem cells out of dormancy, skewed them toward inflammatory monocytes and left lasting epigenetic changes, which the review offers as a molecular basis for residual inflammatory risk after cholesterol is treated. This is preclinical evidence, not yet a clinical recommendation13.

Other sources of low-grade inflammation also feed into this picture. The group's overview of non-traditional risk factors lists gum disease (periodontitis, with a 1.1 to 2.2 fold higher coronary risk in meta-analyses), chronic immune activation, clonal hematopoiesis, gut metabolites and pollutants, all converging on inflammation and oxidative stress2. Rheumatoid arthritis and similar conditions are described as carrying a 50 to 70 percent higher risk of cardiovascular events2. Gokhan's own review with Dr. Hasselbalch examines the links between cardiovascular disease, chronic inflammation and blood stem cell mutations in polycythemia vera14.

The table from the group's overview of non-traditional risk factors: gum disease, immune activation, blood stem cell mutations, the gut microbiome and pollutants, with their mediators, mechanisms and the strength of evidence for each.
The table from the group's overview of non-traditional risk factors: gum disease, immune activation, blood stem cell mutations, the gut microbiome and pollutants, with their mediators, mechanisms and the strength of evidence for each.2

Measuring it: hs-CRP and its limits

What the numbers mean

hs-CRP and regular CRP are the same protein; hs-CRP is simply a more sensitive assay that can detect the small, "silent" background levels relevant to heart disease915. The ACC statement reiterates the usual bands: under 1 mg/L lower relative risk, 1 to 3 mg/L average, and over 3 mg/L higher5. The statement also notes that up to half of US adults have a level of 2 mg/L or higher5.

How well it predicts risk

The strongest numbers in the group come from long-term cohorts:

  • In the Women's Health Study (NEJM 2024), 3,662 first major cardiovascular events occurred over 30 years. Comparing the top with the bottom fifth, the hazard ratio was 1.70 for hs-CRP, 1.36 for LDL cholesterol and 1.33 for lipoprotein(a). Each marker contributed independently, and a combined model gave the widest spread of risk7.
  • The ACC statement also cites a meta-analysis of more than 160,000 people in which each standard-deviation rise in hs-CRP went with a 37 percent higher risk of coronary heart disease and a 55 percent higher risk of cardiovascular death5.
  • In patients with known disease, the statement says hs-CRP is at least as predictive of future events as LDL, even on a statin6.
  • In more than 9,400 statin-treated PCI patients with LDL under 70 mg/dL, hs-CRP of 2 mg/L or more went with about 1.8 times higher major adverse cardiac events, and about 1.9 times when combined with raised triglycerides. Elevated triglycerides alone showed no significant increase. The excess was mostly driven by all-cause mortality3.
Women's Health Study: hs-CRP predicted best of the threeHazard ratio for a first major cardiovascular event, top versus bottom fifth of each marker, 30 years, 3,662 events
*hs-CRP1.70
LDL cholesterol1.36
Lp(a)1.33
Each marker added risk independently, and combining them predicted best. Observational. Source: 7
Show data
Hazard ratio (log scale)95% CI
*hs-CRP1.70–
LDL cholesterol1.36–
Lp(a)1.33–
With LDL under 70, inflammation still carried riskMajor adverse cardiac events in more than 9,400 statin-treated PCI patients, versus those with neither high hs-CRP nor high triglycerides
*High hs-CRP1.8
High hs-CRP plus high triglycerides1.9
High hs-CRP means 2 mg/L or more; high triglycerides means 150 mg/dL or more. High triglycerides alone showed no significant increase. The excess was mostly all-cause deaths. Source: 3
Show data
Relative risk of events (log scale)95% CI
*High hs-CRP1.8–
High hs-CRP plus high triglycerides1.9–

Why a single reading can mislead

Louis Nervegna stresses several caveats:

  • It is systemic. hs-CRP is made by the liver in response to IL-6 and rises with inflammation anywhere, so a high value could reflect a hidden infection, a hard workout the day before or an arthritis flare as easily as a cardiovascular problem915.
  • Temporary spikes. Colds, vaccinations, injuries, surgery, allergic reactions and intense exercise all push it up temporarily, and testing should be avoided during those periods9.
  • It is noisy. It varies greatly from day to day, so it predicts risk best when several measurements taken over a longer period are averaged916.
  • Other drivers. Louis argues that visceral fat and, in older people, ageing skin are major contributors to hs-CRP, and he has also claimed that most circulating CRP originates in skin; he describes the latter as his own claim, not a finding of the Mayo Clinic study he shared1517. A study he shared found higher CRP more likely with overweight or obesity, current smoking, female sex, no statin use, and higher LDL-C and triglycerides18.
  • Age. In the ATTICA analysis of 1,825 Greek adults, a combined IL-6, TNF-alpha and fibrinogen score crossed into the "activated" range by about age 26 in men and 35 in women, whereas CRP itself barely changed with age19.
An infographic of the ATTICA analysis of 1,825 Greek adults: most men had at least one raised inflammation marker by 26 and most women by 35, while CRP barely moved with age. A one-time snapshot, not people followed over time.
An infographic of the ATTICA analysis of 1,825 Greek adults: most men had at least one raised inflammation marker by 26 and most women by 35, while CRP barely moved with age. A one-time snapshot, not people followed over time.19

Other markers

No accepted commercial blood test measures inflammation only in the arteries915. Two candidates are Lp-PLA2 and myeloperoxidase (MPO), which are more artery-specific but, as Louis notes (citing Tom Dayspring), are weak predictors of risk by themselves1516. Louis suggests GlycA, an NMR-measured composite of inflammatory proteins, may prove more useful because it predicts risk well without needing averaging; this is his view, and Dayspring is quoted as calling it far more useful than Lp-PLA2 or MPO16. The ACC statement lists IL-6 and fibrinogen as other predictive markers, but hs-CRP as the most practical5.

Imaging is a different route. The ACC statement calls the CT perivascular fat attenuation index promising but not routine5. Louis shared the CaRi-Heart AI analysis of standard CT angiograms, which reports a coronary-specific Fat Attenuation Index. In one personal case, stenosis had fallen from 70 percent to under 25 percent with LDL at 35 to 50 mg/dL, yet the highest-vessel score was 8.1 (93rd percentile) with an hs-CRP of only 0.15 mg/L, an example of how the blood test and the scan can disagree. Louis believes it may be the best non-invasive measure of residual inflammatory risk, which is his opinion20.

The CaRi-Heart report from the personal case: Fat Attenuation Index scores for each coronary artery plotted against age- and sex-specific percentiles, with the left anterior descending artery at 8.1 (93rd percentile).
The CaRi-Heart report from the personal case: Fat Attenuation Index scores for each coronary artery plotted against age- and sex-specific percentiles, with the left anterior descending artery at 8.1 (93rd percentile).20

One related point: Lp(a) behaves as an acute-phase reactant, so large swings in it usually reflect acute inflammation (infection, surgery, vaccine reactions) rather than an intervention working, and guidelines advise not testing during such periods21.

What the trials show

Proof that inflammation matters

Louis argues that the first major trial showing that lowering arterial inflammation reduces heart attacks and strokes proved that inflammation is causal in cardiovascular disease22. The group's sources point to the CANTOS trial of canakinumab, which blocks IL-1 beta; Gokhan's summary reports a 15 percent reduction in major cardiovascular events without lowering cholesterol223. Libby also cites canakinumab and colchicine as therapies that showed benefit11.

JUPITER enrolled nearly 18,000 people with low LDL but high CRP. According to the Scientific American article, it stopped early with a 54 percent lower risk of heart attack and 48 percent lower risk of stroke on a statin, and those who lowered both cholesterol and CRP were best protected1. Rosuvastatin lowered hs-CRP by 37 percent in that trial24.

Colchicine

Colchicine is an inexpensive anti-inflammatory drug, described in the group as the first heart drug approved for targeting inflammation25. Medscape reported that the FDA approved low-dose colchicine to reduce cardiovascular events in people with established atherosclerotic disease or with multiple risk factors, and Louis stresses that this includes primary prevention for those with multiple risk factors10. The Scientific American article dates that approval to 20231. A Circulation editorial flagged by Gokhan said colchicine shows promise in reducing atherothrombotic risk by stabilizing plaque and reducing inflammation26.

In a randomized CT angiography trial led by Matthew Budoff, 0.5 mg of colchicine daily for one year reduced percent atheroma volume by more than 1 percent versus placebo, with a significant fall in CRP, trends toward regression of non-calcified plaque, and slower progression of calcified plaque. Budoff called it a relatively small study that supports colchicine in chronic stable coronary disease27. Louis also lists colchicine among six strategies with randomized evidence for plaque regression28. He has speculated that colchicine may work partly by inhibiting IL-11, a pro-fibrotic cytokine from the IL-6 family; he labels this a hypothesis2529.

Nuances and controversies

Is inflammation a cause or a bystander?

The group's debate posts show real disagreement. In a Libby versus Raal debate, Libby argued there is substantial residual inflammatory risk even with well-controlled LDL and that IL-6 is causal; Raal argued LDL is the primary cause, with inflammation a consequence that can mostly be handled by lifestyle and weight loss. Both agreed that addressing lipids and inflammation has value30. Louis, for his part, frames inflammation as an independent risk factor that persists even when classical risk factors are well managed14.

The ZEUS result

IL-6 looked like a logical target, but ZEUS tested it directly. In 6,376 people with clogged arteries, chronic kidney disease and high CRP, monthly ziltivekimab lowered CRP by 64 percent and IL-6 by 76 percent, yet heart attack, stroke or cardiovascular death occurred in 17.6% versus 17.7% on placebo over 33 months, with more serious infections in the treated group831. A companion post stresses that this is why outcomes matter more than improved bloodwork23.

ZEUS: inflammation markers plunged, events did notChange with monthly ziltivekimab versus placebo in 6,376 people with atherosclerosis, chronic kidney disease and high CRP
IL-6−76%
CRP−64%
Heart attack, stroke or cardiovascular death: 17.6% on ziltivekimab versus 17.7% on placebo over 33 months, with more serious infections on the drug. Source: 831
Show data
Value
IL-6−76%
CRP−64%

How to interpret this is debated within the posts:

  • The summary of the two trials notes that all participants already had disease, so ZEUS does not prove inflammation is not causal8.
  • One commenter suggested that with LDL already low there may have been less room left to show benefit31.
  • Louis argues IL-6 may be a marker of a broader inflammatory pattern, more like HDL than a direct cause, and that diet and colchicine work because they address the whole pattern31.
  • He adds that interventions addressing upstream causes, such as statins and diet, seem to work better than blocking inflammation downstream, and that NSAIDs and corticosteroids lower hs-CRP yet make heart disease worse. He stresses this does not mean inflammation is not causal24.

The same lesson appears in the posts on earlier failures, such as the HDL-raising drug torcetrapib, where events worsened despite a better lab number8.

Are seed oils inflammatory?

Many people assume omega-6 seed oils drive inflammation. Louis points to a meta-analysis of 30 randomized trials (1,377 people) in which higher linoleic acid intake had no significant effect on TNF, IL-6, adiponectin or MCP-1, and CRP (16 studies) was not significantly changed (standardized mean difference 0.09, 95% CI -0.05 to 0.24)323334. In the Framingham Offspring and Omni cohorts (2,777 people), higher red blood cell linoleic acid correlated weakly but inversely with CRP (r = -0.06) and soluble IL-6 (r = -0.15)35. A cross-sectional analysis of 1,894 people found similar associations, though it cannot show causation3637. Louis concludes that avoiding seed oils is not a way to lower CRP38. A very small 2026 trial of 10 adults on 30 g soybean oil daily also saw arachidonic acid fall39.

How to lower it: what the group discusses

Lifestyle

The ACC statement stresses lifestyle: at least 150 minutes of exercise per week, a Mediterranean or DASH diet, and two to three fatty-fish meals per week for EPA and DHA6. Louis cites a meta-analysis of 30 trials (3,106 people) in which olive oil lowered CRP by 0.64 mg/L and IL-6 by 0.29, and improved flow-mediated dilation40. An analysis of blood samples from the COSMOS cocoa trial reported that cocoa extract lowered hsCRP by 8.4 percent per year versus placebo in 598 participants; Louis notes the main COSMOS trial reported 27 percent lower cardiovascular mortality, and Gokhan says he eats cocoa but does not supplement4142.

On the downside, a clip Louis shared reported that one 20-ounce sugar-sweetened drink daily for three weeks doubled hs-CRP in healthy young men, with a rise in small dense LDL43. Weight loss is also listed among strategies with randomized evidence for plaque regression28. A podcast claim that running helps depression, especially in people with high inflammation, is secondhand and without named studies44.

Drugs that lower hs-CRP

  • Statins. A 2022 meta-analysis of 26 randomized trials found statins lowered hs-CRP by about 0.97 mg/L (95% CI -1.26 to -0.68) in people with cardiovascular disease, in both high- and lower-intensity regimens; Louis notes this is roughly a 50 percent fall from a starting value of 2 mg/L4546. He also suggests statins may lower hs-CRP partly by stabilizing inflamed plaque24.
  • Other lipid-lowering drugs. Louis summarizes average hs-CRP reductions from meta-analysis data as about 17.3 percent for statins, 20 percent for bempedoic acid, 10.3 percent for fibrates, 6 percent for PCSK9 inhibitors and 3.2 percent for ezetimibe, versus about 12.8 percent for fish oil; the paper's own illustration, shared in the same post, shows PCSK9 inhibitors slightly raising hs-CRP rather than lowering it, and the fibrate reduction as not statistically significant12. The Cardiovascular Research meta-analysis found statins, bempedoic acid, ezetimibe and omega-3s reduced CRP independently of LDL-C47. A bempedoic acid outcomes study in 4,206 statin-intolerant patients reported a 30 percent lower primary composite, with hs-CRP down 21.5 percent48.
  • Plaque-level markers. A review quoted by Louis found four statins lowered Lp-PLA2, and adding ezetimibe lowered it more49.
  • Others in the group. Pioglitazone lowered hsCRP and raised adiponectin in small plaque trials in people with diabetes50. Small trials found taurine (3 g/day for 8 weeks in type 2 diabetes) and ginger (1,600 mg/day for 8 weeks in 57 men) lowered hs-CRP5152. Gokhan shares a personal list of anti-inflammatory drugs and supplements without cited trials53, and his own hs-CRP fell from about 1.2 to 0.254. These are limited or personal evidence, not outcome trials.
How much lipid drugs and fish oil lower hs-CRPAverage reduction in hs-CRP, from meta-analysis data summarized by Louis
Bempedoic acid−20%
Statins−17.3%
Fish oilabout −12.8%
Fibrates−10.3%
Ezetimibe−3.2%
Averages across different trials; part of the effect comes from lowering LDL itself. The fibrate result was not statistically significant, and PCSK9 inhibitors are left out because the paper's illustration shows them slightly raising hs-CRP. Source: 12
Show data
Value
Bempedoic acid−20%
Statins−17.3%
Fish oilabout −12.8%
Fibrates−10.3%
Ezetimibe−3.2%

Still preclinical

A University of Pennsylvania study engineered regulatory T cells to target oxidized LDL and cut plaque by 70 percent in mice. It is a long way from patients55.

What this means for you

  • The group's admins suggest asking a doctor about an hs-CRP test alongside cholesterol, since the ACC statement recommends universal screening and its authors say "the time for taking action has now arrived"5656.
  • Test when well, avoiding the days after infections, vaccines, hard workouts or surgery, and consider repeating it and averaging916.
  • A high value deserves a look at obvious sources such as infection, gum disease, arthritis and visceral fat, since hs-CRP does not point to the arteries215.
  • Do not neglect LDL. Inflammation and LDL work together, and the group's sources favor fixing upstream causes through lipids, diet and exercise1224.
  • Colchicine is an FDA-approved option for people with established disease or multiple risk factors, to be discussed with a cardiologist1027.
  • Prefer treatments proven on outcomes over lab numbers, as ZEUS shows823.

Frequently asked questions

Is hs-CRP the same as CRP?

Same protein, different sensitivity. hs-CRP detects the small background levels relevant to heart disease, while regular CRP is adequate for large spikes such as autoimmune disease9.

What is a "good" hs-CRP level?

The ACC statement's bands are under 1 mg/L lower risk, 1 to 3 average, over 3 higher5. Gokhan reports his own reading fell from about 1.2 to 0.254.

If my LDL is low, can inflammation still matter?

Yes, according to the sources. In statin-treated PCI patients with LDL under 70, elevated hs-CRP carried about 1.8 times more events3, and Ridker is quoted saying that low LDL on a statin does not mean you are home free4.

Why did ZEUS fail if inflammation is causal?

It is debated: patients already had disease, LDL may have been low, and IL-6 may be a marker for a broader pattern rather than the lever itself831.

Do seed oils raise CRP?

Trial meta-analyses found no significant effect of linoleic acid on CRP or IL-63234.

The evidence behind this summary51 studies · 6 meta-analyses · 19 trials · 8 observational

The 56 group posts cited above discuss 51 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 6Randomized trials 19Observational studies 8Reviews & guidelines 7Animal & lab studies 4Other sources 7

Strongest evidence discussed

All 51 studies and sources
Sources from the group (56)
  1. Scientific American: inflammation is a heart risk factor independent of LDL, BP, diabetes Louis Nervegna · Apr 18, 2026 · Facebook
  2. Non-traditional heart disease risk factors converge on inflammation and oxidative stress Gokhan Can · Aug 29, 2025 · Facebook
  3. In statin-treated PCI patients with LDL <70, inflammation, not TG, gave ~1.8x more MACE Louis Nervegna · Apr 20, 2026 · Facebook
  4. Inflammation is a causal risk factor; CRP predicts heart disease as well as LDL (Ridker) Louis Nervegna · Jun 20, 2025 · Facebook
  5. 2025 ACC statement: inflammation is actionable in CVD, with universal hsCRP screening Gokhan Can · Oct 09, 2025 · Facebook
  6. 2025 ACC statement: inflammation in ASCVD is compelling and clinically actionable Louis Nervegna · Sep 30, 2025 · Facebook
  7. NEJM: hs-CRP, LDL and Lp(a) each predicted 30-year CVD risk in women, best combined Louis Nervegna · Aug 31, 2024 · Facebook
  8. Pelacarsen (Lp(a)HORIZON) and ziltivekimab (ZEUS) cut their targets but not heart events Louis Nervegna · Nov 13, 2026 · Facebook
  9. What CRP and hs-CRP actually measure, and why a single reading is unreliable Louis Nervegna · Oct 27, 2025 · Facebook
  10. FDA approved low-dose colchicine for CV risk reduction, including multiple risk factors Louis Nervegna · Jun 20, 2025 · Facebook
  11. Peter Libby on inflammation in atherosclerosis, CHIP, canakinumab and colchicine Gokhan Can · Feb 17, 2024 · Facebook
  12. Statins, bempedoic acid, ezetimibe, fibrates and PCSK9 inhibitors all lower hsCRP Louis Nervegna · Dec 28, 2025 · Facebook
  13. Cholesterol as a master regulator of blood stem cells, driving inflammatory hematopoiesis Gokhan Can · Oct 19, 2025 · Facebook
  14. Mergen and Hasselbalch review heart drugs, supplements and lifestyle in polycythemia vera Gokhan Can · Jun 11, 2026 · Facebook
  15. hsCRP is not artery-specific: aging skin and visceral fat drive it in older people Louis Nervegna · Jun 28, 2026 · Facebook
  16. hsCRP needs averaging; GlycA may be a better inflammation marker than Lp-PLA2 or MPO Louis Nervegna · Aug 08, 2026 · Facebook
  17. Mayo Clinic study: skin generates senescent cells that may age the heart and other organs Louis Nervegna · Oct 23, 2024 · Facebook
  18. Higher CRP is more likely with obesity, smoking, female sex, no statin, high LDL-C and TG Louis Nervegna · Apr 09, 2026 · Facebook
  19. Inflammaging may begin around age 26 in men and 35 in women, ATTICA analysis finds Louis Nervegna · Nov 09, 2026 · Facebook
  20. CaRi-Heart AI on CT angiograms measures coronary inflammation missed by hs-CRP Louis Nervegna · Sep 18, 2026 · Facebook
  21. Big swings in Lp(a) usually reflect acute inflammation, not an intervention working Louis Nervegna · Jun 20, 2026 · Facebook
  22. Ten game-changing recent cardiology RCTs, incl. the one showing inflammation is causal Louis Nervegna · Jul 21, 2025 · Facebook
  23. Preview of HORIZON (Lp(a)) and ZEUS (IL-6): improved bloodwork is not enough Louis Nervegna · Nov 06, 2026 · Facebook
  24. Statins may lower hsCRP by stabilizing plaque; fixing upstream causes beats blocking IL-6 Louis Nervegna · Aug 10, 2026 · Facebook
  25. Colchicine may work partly by inhibiting IL-11, a lifespan-linked pro-fibrotic cytokine Louis Nervegna · Jul 26, 2024 · Facebook
  26. Colchicine may stabilize plaques and cut atherothrombotic risk: Circulation editorial Gokhan Can · Sep 27, 2024 · Facebook
  27. Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff) Louis Nervegna · May 11, 2025 · Facebook
  28. Six strategies shown to regress plaque in human randomized trials Louis Nervegna · Feb 27, 2025 · Facebook
  29. Blocking IL-11 extended mouse lifespan ~25%; diets and drugs that may lower it listed Louis Nervegna · Jul 17, 2024 · Facebook
  30. Libby vs Raal debate: is inflammation or LDL the key driver of CVD risk? Gokhan Can · Oct 19, 2024 · Facebook
  31. ZEUS: ziltivekimab cut hsCRP and IL-6 but did not reduce cardiovascular events Louis Nervegna · Aug 01, 2026 · Facebook
  32. Over 30 RCTs show omega-6 linoleic acid does not raise inflammatory markers Louis Nervegna · Feb 07, 2024 · Facebook
  33. 30 RCTs (1,377 people): more linoleic acid did not raise CRP, IL-6 or TNF Louis Nervegna · Oct 15, 2025 · Facebook
  34. A 30-RCT meta-analysis found linoleic acid does not raise inflammatory markers Louis Nervegna · Aug 06, 2025 · Facebook
  35. Higher red blood cell omega-6 linked to lower inflammation markers in Framingham Offspring Louis Nervegna · Apr 16, 2026 · Facebook
  36. Higher plasma linoleic acid tied to lower glucose, insulin and inflammation (n=1,894) Louis Nervegna · Jun 02, 2025 · Facebook
  37. Higher blood linoleic acid linked to lower inflammation and cardiometabolic risk Louis Nervegna · Jun 04, 2025 · Facebook
  38. Avoiding seed oils does not lower CRP or other inflammatory markers Louis Nervegna · Nov 22, 2023 · Facebook
  39. Soybean oil 30 g/day lowered arachidonic acid in a 2026 trial; 30+ RCTs: not inflammatory Louis Nervegna · Oct 22, 2026 · Facebook
  40. Meta-analysis of 30 trials: olive oil lowers CRP and IL-6 and improves FMD Louis Nervegna · Mar 14, 2025 · Facebook
  41. COSMOS cocoa extract lowers hsCRP in older adults, possibly explaining CVD benefit Louis Nervegna · Sep 17, 2025 · Facebook
  42. Cocoa extract supplement lowered hsCRP in older adults, reports COSMOS-based news Gokhan Can · Sep 26, 2025 · Facebook
  43. One sugar-sweetened soda daily for 3 weeks doubled CRP and raised small dense LDL Louis Nervegna · Apr 18, 2025 · Facebook
  44. Running may treat depression as well as SSRIs, relevant because depression raises CVD risk Louis Nervegna · Jul 11, 2025 · Facebook
  45. Meta-analysis of 26 RCTs: statins lowered hs-CRP by about 1 mg/L in patients with CVD Louis Nervegna · Jul 12, 2024 · Facebook
  46. ACC urges measuring hsCRP; statins cut hsCRP about 1 mg/L in a 26-RCT meta-analysis Louis Nervegna · Oct 09, 2025 · Facebook
  47. Meta-analysis: statins, bempedoic acid, ezetimibe and omega-3 lower CRP independent of LDL Gokhan Can · Feb 19, 2024 · Facebook
  48. Bempedoic acid cut CV events and may also dampen age-related inflammation Louis Nervegna · Jul 21, 2026 · Facebook
  49. Statins, especially with ezetimibe, lower Lp-PLA2, a plaque-specific inflammation marker Louis Nervegna · Jun 22, 2025 · Facebook
  50. Pioglitazone slowed coronary plaque progression and shrank necrotic core in diabetics Gokhan Can · Jan 14, 2025 · Facebook
  51. Taurine 3 g/day lowered insulin, HOMA-IR and inflammation in type 2 diabetes RCT Louis Nervegna · Jul 04, 2026 · Facebook
  52. Ginger 1,600 mg/day for 8 weeks lowered Lp(a), hsCRP and fasting glucose in a small RCT Louis Nervegna · Apr 28, 2026 · Facebook
  53. A personal list of anti-inflammatory drugs and supplements, with low-dose colchicine next Gokhan Can · Feb 18, 2024 · Facebook
  54. One admin's story: high-risk blood disorder, LDL 70, hsCRP down from 1.2 to 0.2 Gokhan Can · Dec 05, 2023 · Facebook
  55. Engineered regulatory T cells targeting oxidized LDL cut plaque 70% in mice Gokhan Can · Nov 22, 2025 · Facebook
  56. ACC recommends broader hsCRP testing to detect low-grade inflammation Louis Nervegna · Oct 05, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary